Background and Purpose: The effects of substance P (SP) and calcitonin gene-related peptide (CGRP) were tested on pial arterioles of mice. This was done because (1) perivascular peptidergic nerves may play an important role in modulation of cerebrovascular responses; (2) there are conflicting data concerning the mechanism of action of CGRP; (3) there are few or no studies directly testing the endothelium dependence of dilation by these peptides in the cerebral circulation; and (4) we wished to extend previous observations of mice by comparing peptidergic responses in the mouse with those published for other species.
F or many years we have used mouse pial arterioles as an in vivo model of the cerebral vasculature. Many of our observations are useful in understanding cerebrovascular control mechanisms in other species, for example, our demonstration of endothelium-dependent vasodilation. 12 The following studies of peptide action on these vessels was undertaken for two reasons. First, we wished to see if mouse pial arterioles reacted to calcitonin gene-related peptide (CGRP) and substance P (SP) as do cerebral vascular beds in other species. Such a similarity would complement previously demonstrated similarities between mouse pial vessels and the cerebral vessels of other species. Second, we wished to study these particular peptides because of the recent important findings concerning the possible relation of these vasodilators to cerebrovascular control. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These peptides are contained within nerves innervating the cerebral blood vessels. 3 Recently, some peptides have been shown to play a role in mediating the a neuropeptide may mediate the vasodilation produced by local application of nitrosodilators to cat pial vessels.11 The studies reported below include direct testing of the endothelium-dependent action of CGRP and SP and also utilize inhibitors of dilations mediated by the endothelium-derived relaxing factor for acetylcholine (EDRFACh), a mediator of undetermined chemical composition in cerebrovascular endothelium. 13 The studies of endothelium dependence and its relation to EDRFACh are of interest in view of conflicting data concerning several different vascular beds and the endothelium dependence of CGRP in particular.3"14-20 
Experimental Design
Each mouse underwent a 30-minute period of equilibration with the Elliott's solution. CGRP was applied as a 1-mL bolus over a period of 1 minute. Substance P was applied as a 3-mL bolus over a 3-minute period. Successive doses were 15 minutes apart. When the laser-dye combination was used, the dye was injected at the beginning of the 30-minute equilibration period.
The dilating drug was then tested. Five minutes later, the laser was permitted to hit the vessel. Ten minutes later, a second application of the dilator was made. Fifteen minutes later, a third application was made at a site 100 ,um from the site of injury. This last application served as a "time control" to show no deterioration of the preparation over time.
When L-NMMA, D-NMMA, or NNA was used, only one of these drugs was tested per study. L-NMMA and NNA were used because they prevent dilation mediated by EDRFACh. This may be because they inhibit the enzyme synthesizing EDRFACh.31'32 However, in this preparation they appear to work by generating an oxygen-centered free radical via an incompletely defined pathway. 33 The radical destroys EDRFACh.34 '35 D-NMMA was also used in our investigation as a control because it is reported to be the inactive enantiomer of L-NMMA. 31 The suffusion of these drugs began 10 minutes before application of the peptide, and they were also present in the solution containing the peptide. In each study, five mice were first tested with dilator alone followed by peptide plus drug. The sequence was reversed in five additional mice. Sequence had no effect on outcome, so the two groups were combined, giving n=10.
Indomethacin was tested in the manner described for L-NMMA. The high dose used (40 ,ug/mL) was selected because it was required to block constriction by 10 ,gg/mL sodium arachidonate in these mice.
Statistics
Since each arteriole served as its own control and the data were expressed as a percent change in diameter, the responses before and after treatment were compared using the Wilcoxon matched pairs test.36 A treatment effect was considered significant when the null hypothesis was rejected at the .05 level. Although the data were not analyzed using a comparison of means, the means and standard deviations are always given as a convenient way of presenting the results.
Results CGRP relaxed vessels in a dose-dependent fashion. When 108, 10 ', and 10-6 mol/L doses were given to one set of mice (n=4), the diameter (39±2 ,um) increased 5+1%, 6±2%, and 13±5% (mean±SD), respectively. Responses differed moderately in magnitude in different sets of mice, but whenever it was tested, a dose response was always observed. The reason for different magnitudes of response in different groups could not be explained. SP 10-6 to 10-4 mol/L also dilated pial arterioles, but a definite dose response was not found. The reasons for this were unclear. Tachyphylaxis sometimes appeared with diminution but not loss of response to a second dose given 15 minutes after the first. However, no tachyphylaxis was noted to SP in studies of the action of D-NMMA, and there was no influence of treatment sequence on the results of the study in which SP was given twice, once with and once without L-NMMA.
Both the dilations by CGRP and by SP were markedly inhibited by endothelial injury. This is shown in Table 1 . For CGRP, in 4 of the 10 mice, the response to CGRP was completely blocked by the injury. In all 10 mice, the response to CGRP was intact 100 ,.m away from the injury, showing that the diminished response at the injured site was not caused by deterioration of the preparation over time. In fact, the mean increase in diameter at the distant site was 7±2%, identical to the original preinjury response in the adjacent arteriolar segment. In the case of SP, endothelial injury totally abolished the response in 9 of 10 mice. Again, a third test of the peptide, 15 minutes later and 100 gtm away, showed a full response to SP. Consequently, the loss of response at the injured site cannot be due to tachyphylaxis or to fatigue of the preparation.
The In the studies of the action of L-NMMA or NNA on CGRP or SP, we first selected concentrations of the arginine analogues that we knew had little or no effect on diameter. This was confirmed by the present results. In all except one study, at least half the vessels showed no change in diameter after 10-minute suffusion by arginine analogue, whereas constriction was seen in the remaining vessels. The effects of L-NMMA or NNA on dilation by peptide were the same whether the vessel was or was not constricted by the arginine analogue. CGRP was inhibited by both L-NMMA 10-6 and NNA 10-5 (Table 2 ). We previously showed that Therefore, we attempted to inhibit SP with the inhibitor of cyclooxygenase, indomethacin. However, 40 ,ug/mL of indomethacin failed to inhibit the dilation by either CGRP or SP. In the case of SP, 10-4 dilated vessels 7+2% before and 7+2% during indomethacin (40 ,ug/mL) treatment (n=6). The indomethacin itself failed to alter diameter. In the case of CGRP, mol/L dilated vessels 4+1% before and 5+±1% during indomethacin treatment.
Discussion
These data show that in mice, dilation by both CGRP and SP is endothelium dependent. This conclusion is based on observations before and after endothelial injury rather than merely on the presence or absence of inhibition by an inhibitor of EDRFACh synthesis. Studies in the literature often use such inhibitors to examine the endothelium dependence of a response. Inhibition by The endothelium-dependent dilation by SP was only slightly impaired by low-dose L-NMMA but was blocked by high-dose (10`4 mol/L) L-NMMA. The effect of the higher dose on SP was still stereospecific, since D-NMMA had no effect at that dose. The conventional interpretation of the SP data is that SP produces dilation via EDRFACh. We have no reason to offer another explanation. The responses to SP were not dose dependent. We have no definitive explanation for this. However, a slight constriction to SP was unmasked by endothelial damage. It may be that with increasing doses of SP, there are parallel increases of both dilating and constricting actions resulting in no net increase in the magnitude of the resultant dilation.
Neither CGRP nor SP were inhibited by a high dose of indomethacin. Thus, endothelium-derived prostanoids do not appear to be implicated as mediators of the dilation.
Our finding that SP is endothelium dependent is similar to virtually all reports of SP action both within and outside of the cerebral vasculature.3"5"14'37 However, our finding that CGRP is endothelium dependent contradicts other reports concerning brain blood vessels3.15 and contradicts some reports concerning other vascular beds.'1420 We do not know if this represents a species difference, a difference in size of vessels studied, or a difference related to the in vitro nature of the latter studies14'20 as opposed to the in vivo technique used here. However, several other in vitro investigations of extracerebral vessels have concluded as we have that CGRP is endothelium dependent. [16] [17] [18] [19] In some of these cases, the action of CGRP has been inhibited by arginine analogues17 '19 as in this study, thus implicating EDRFACh as the mediator. Some workers failed to find an elevation of cyclic guanosine monophosphate (cGMP) after CGRP treatment. 18 They concluded from this that even though CGRP was endothelium dependent, EDRFACh could not be the mediator, since EDRFACh is thought to produce dilation via an increase of cGMP. However, others show that CGRP can indeed elevate cGMP in rodent aorta. 16 Mouse pial vessels appear to fit into that group of vessels whose responses to CGRP are dependent on an endothelium-derived mediator resembling EDRFACh. However, this conclusion is largely based on complete inhibition of response by L-NMMA. Since even high concentrations of NNA only partially inhibited the response to CGRP, it is theoretically possible that L-NMMA might be acting by two mechanisms, one against EDRFACh and one undefined. EDRFACh then would be one of two endotheliumderived mediators of CGRP action. The other mediator would also be L-NMMA sensitive. It would not be a product of cyclooxygenase activity because indomethacin had no effect on the action of CGRP.
In summary, our findings indicate that in mice as in other species, dilation of pial vessels by peptides can occur via an endothelium-dependent route. This is shown first by demonstrating loss of the response after endothelial damage in vivo. Such a demonstration appears to us to be more direct than the more common technique using a pharmacological inhibitor of some known endothelium-dependent pathway. When we used such pharmacological techniques, the data implicated EDRFACh as the mediator for both CGRP and SP. The demonstration of endothelium-dependent dilation by CGRP is at variance with other reports.315 However, we cannot find reports concerning CGRP, endothelium dependence, and pial vessels in species other than the cat. Therefore, no conclusions can be drawn with respect to whether the response of murine pial arterioles to CGRP is typical or atypical of mammalian pial vessels. Considered together, the demonstration of endothelium dependence, the known localization of CGRP and SP in perivascular nerves,3,6'10 and the effects of trigeminal ganglionectomy or related procedures on cerebrovascular regulation6-10,12 support the assumption that peptides released by nerves can elicit vasodilation by traversing the vascular wall and reaching the endothelium, where they, release EDRFACh.
Editorial Comment
The accompanying article by Rosenblum et 
